[Federal Register Volume 81, Number 171 (Friday, September 2, 2016)]
[Notices]
[Page 60710]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21113]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Development of
Integrin [alpha]v[beta]3 Antagonists for Use in Imaging and Therapy
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR part 404.7(a)(1)(i), that the National Cancer Institute (NCI) and
the Clinical Center (CC), National Institutes of Health, Department of
Health and Human Services, are contemplating the grant of an exclusive
license to Advanced Imaging Projects, LLC, a company having a place of
business in Boca Raton, FL, to practice the inventions embodied in the
following patent applications:
Intellectual Property
U.S. Patent No. 7,300,940, filed 4 August 2004, titled ``Integrin
[alpha]-v [beta]-3 antagonists for use in imaging and therapy'' (HHS
Ref. No.: E-170-2004/0-US-01);
PCT Application No. PCT/US2005/027868, filed 3 August 2005, now
abandoned, titled ``Integrin [alpha]-v [beta]-3 antagonists for use in
imaging and therapy'' (HHS Ref. No.: E-170-2004/0-PCT-02);
Switzerland Patent No. 1781622, titled ``Integrin [alpha]-v [beta]-
3 antagonists for use in imaging and therapy'' filed 4 March 2007,
issued 18 May 2011 (HHS Ref. No.: E-170-2004/0-CH-04);
Germany Patent No. 602005028137.1, titled ``Integrin [alpha]-v
[beta]-3 antagonists for use in imaging and therapy'' filed 4 March
2007, issued 18 May 2011 (HHS Ref. No.: E-170-2004/0-DE-05);
France Patent No. 1781622, titled ``Integrin [alpha]-v [beta]-3
antagonists for use in imaging and therapy'' filed 4 March 2007, issued
18 May 2011 (HHS Ref. No.: E-170-2004/0-FR-060); and
Ireland Patent No. 1781622, titled ``Integrin [alpha]-v [beta]-3
antagonists for use in imaging and therapy'' filed 4 March 2007, issued
18 May 2011 (HHS Ref. No.: E-170-2004/0-IE-07).
The patent rights in these inventions have been assigned to the
Government of the United States of America. The territory of the
prospective exclusive license may be worldwide, and the field of use
may be limited to ``Conjugate of Alpha-V beta-3 antagonist NIH-CC-013
for theranostic application to diagnose, prevent and treat oncological,
infectious, ocular and cardiovascular disorders.''
DATES: Only written comments and/or applications for a license which
are received by the NCI Technology Transfer Center on or before
September 19, 2016 will be considered.
ADDRESSES: Requests for copies of the patent application(s), inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Jaime M. Greene, M.S., Senior Licensing
and Patenting Manager, Technology Transfer Center, National Cancer
Institute, 9609 Medical Center Drive, Rockville, MD 20850; telephone:
240-276-6633; email: [email protected].
SUPPLEMENTARY INFORMATION: This technology concerns small molecule
compositions that are antagonists for the receptor integrin
[alpha]v[beta]3. Integrins are functional molecules for cell adhesion
activity that are expressed by the majority of normal and cancer cells.
They are trans-membrane heterodimer receptors that include two
subunits, [alpha] and [beta] chains, that primarily allow cell adhesion
to extracellular matrix components such as fibrillar collagen,
vitronectin and osteopontin. This technology may be useful for the
development of diagnostics and therapeutics for cancers and other
conditions involving the integrin [alpha]v[beta]3.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404.7. The prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.7.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Patent License Agreement.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: August 29, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2016-21113 Filed 9-1-16; 8:45 am]
BILLING CODE 4140-01-P